A Study of V132 in Healthy Older Participants (V132-001)
A Phase 1, Randomized, Double-Blind, Comparator-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V132 in Healthy Older Participants
The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Toll Free Number
- 电话号码:1-888-577-8839
- 邮箱:Trialsites@msd.com
学习地点
-
-
California
-
Anaheim、California、美国、92801
- 招聘中
- Anaheim Clinical Trials ( Site 0006)
-
接触:
- Study Coordinator
- 电话号码:714-774-7777
-
-
Florida
-
Hallandale、Florida、美国、33009
- 招聘中
- Velocity Clinical Research, Hallandale Beach ( Site 0003)
-
接触:
- Study Coordinator
- 电话号码:954-455-5757
-
Hollywood、Florida、美国、33024
- 招聘中
- Research Centers of America ( Hollywood ) ( Site 0009)
-
接触:
- Study Coordinator
- 电话号码:954-990-7649
-
South Miami、Florida、美国、33143
- 招聘中
- QPS-MRA, LLC-Early Phase ( Site 0001)
-
接触:
- Study Coordinator
- 电话号码:305-722-0970
-
-
Missouri
-
Springfield、Missouri、美国、65802
- 招聘中
- Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
-
接触:
- Study Coordinator
- 电话号码:417-831-2048
-
-
Nebraska
-
Lincoln、Nebraska、美国、68510
- 招聘中
- Velocity Clinical Research Lincoln ( Site 0007)
-
接触:
- Study Coordinator
- 电话号码:531-530-2800
-
Omaha、Nebraska、美国、68134
- 招聘中
- Velocity Clinical Research, Omaha ( Site 0008)
-
接触:
- Study Coordinator
- 电话号码:402-933-6500
-
-
Ohio
-
Columbus、Ohio、美国、43215
- 招聘中
- Remington-Davis, Inc. ( Site 0005)
-
接触:
- Study Coordinator
- 电话号码:614-487-2560
-
-
Rhode Island
-
East Greenwich、Rhode Island、美国、02818
- 招聘中
- Velocity Clinical Research, Providence ( Site 0010)
-
接触:
- Study Coordinator
- 电话号码:401-739-9350
-
-
Texas
-
League City、Texas、美国、77573
- 招聘中
- University of Texas Medical Branch ( Site 0004)
-
接触:
- Study Coordinator
- 电话号码:832-340-2313
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
The key inclusion criteria include but are not limited to the following:
- Is in good health
- Has body mass index (BMI) within 18.0 to 35.0 kg/m^2 (inclusive)
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
- Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination
- Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1: Dose Escalation
Participants will receive single intramuscular (IM) doses of a V132 formulation or comparator regimen at varying dose levels. |
Experimental Experimental Experimental Active Comparator Active Comparator |
|
实验性的:Part 2: Dose Expansion
Participants will receive single IM doses of a V132 formulation or comparator regimen. Doses will be determined based on review of Part 1 data and will not exceed maximum dose level assessed in Part 1. |
Experimental Experimental Experimental Active Comparator Active Comparator |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants with Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
大体时间:Up to approximately 30 minutes post vaccination
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with immediate reactions occurring within 30 minutes after any vaccination will be reported. |
Up to approximately 30 minutes post vaccination
|
|
Percentage of Participants with a Solicited Injection-site Adverse Event
大体时间:Up to approximately 7 days post vaccination
|
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited injection-site AEs assessed are redness/erythema, swelling, and tenderness/pain. The percentage of participants with a solicited injection-site adverse event will be reported. |
Up to approximately 7 days post vaccination
|
|
Percentage of Participants with a Solicited Systemic Adverse Event
大体时间:Up to approximately 7 days post vaccination
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The solicited systemic AEs assessed are muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with a solicited systemic adverse event will be reported. |
Up to approximately 7 days post vaccination
|
|
Percentage of Participants With at Least 1 Unsolicited Adverse Event
大体时间:Up to approximately 28 days post vaccination
|
An unsolicited AE is an AE that was not solicited using a vaccination report card (VRC) and that is communicated by a participant (or their legally acceptable representative, if applicable). Unsolicited AEs include serious and nonserious AEs. The percentage of participants with at least 1 unsolicited adverse event will be reported. |
Up to approximately 28 days post vaccination
|
|
Percentage of Participants with a Serious Adverse Event
大体时间:Up to approximately 12 months post vaccination
|
A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event. The percentage of participants that experienced 1 or more SAEs will be reported. |
Up to approximately 12 months post vaccination
|
|
Percentage of Participants With at Least 1 Medically Attended Adverse Event
大体时间:Up to approximately 12 months post vaccination
|
A medically attended adverse event (MAAE) is an AE in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency room visit, office visit, or an urgent care visit with any medical personnel for any reason. The percentage of participants with at least 1 MAAE will be reported. |
Up to approximately 12 months post vaccination
|
|
Percentage of Participants Who Experienced an Adverse Event of Clinical Interest
大体时间:Up to approximately 12 months post vaccination
|
Events of clinical interest (ECIs) are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs). The percentage of participants who experienced an adverse event of clinical interest will be reported. |
Up to approximately 12 months post vaccination
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA)
大体时间:Up to approximately 28 days post vaccination
|
Opsonophagocytic activity (OPA) for serotypes in V132 formulations will be determined using a multiplexed opsonophagocytic assay (MOPA). Geometric Mean Titer (GMT) of serotype-specific OPA will be reported. |
Up to approximately 28 days post vaccination
|
|
Geometric Mean Fold Rise from Baseline of Serotype-specific OPA
大体时间:Baseline (pre-vaccination) and 28 days post vaccination
|
The Geometric Mean Fold Rise (GMFR) from baseline in serotype-specific OPA GMTs for serotypes in V132 formulations will be determined using a multiplexed opsonophagocytic assay (MOPA). GMFR is defined as the geometric mean of the ratio of concentration at Day 28 post vaccination divided by concentration at baseline. |
Baseline (pre-vaccination) and 28 days post vaccination
|
合作者和调查者
调查人员
- 研究主任:Medical Director、Merck Sharp & Dohme LLC
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- V132-001
- V132-001 (其他标识符:MSD)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.